Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16582319 | 1.00 | HSD17B10 (0.45) | HSD17B10SIGMAR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL26757497 | 1.00 | HSD17B10 (0.45) | HSD17B10SIGMAR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL20686921 | 1.00 | HSD17B10 (0.45) | HSD17B10SIGMAR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL29299531 | 1.00 | HSD17B10 (0.45) | HSD17B10SIGMAR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL12605349 | 0.93 | SIGMAR1 (0.54) | HSD17B10SIGMAR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL17022247 | 0.93 | SIGMAR1 (0.54) | HSD17B10SIGMAR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL126194 | 0.91 | HSD17B10 (0.52) | HSD17B10KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL21547377 | 0.91 | HSD17B10 (0.52) | HSD17B10KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL5517050 | 0.91 | HSD17B10 (0.52) | HSD17B10KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL16645332 | 0.91 | HSD17B10 (0.52) | HSD17B10KMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | HSD17B10 3848/4885SIGMAR1 231/4885KMT2A 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.